METHOTREXATE SODIUM

Post-LOE

methotrexate sodium

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Feb 1999

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METHOTREXATE SODIUM (methotrexate sodium) by Fresenius Kabi is clinical pharmacology: methotrexate inhibits dihydrofolic acid reductase. Approved for the treatment of gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole and 15 more indications. First approved in 1999.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with…

Worked on METHOTREXATE SODIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

METHOTREXATE SODIUM

Mechanism of Action

Indications (16)